NCT06132126

A Study to Investigate the Safety and Tolerability of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

A Single and Multiple-Ascending Dose Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3938577 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to assess the safety and tolerability of a single dose of LY3938577 in healthy participants and participants with Type 2 Diabetes Mellitus (T2DM) (Part A) and multiple doses of LY3938577 in participants with T2DM (Part B). The study will last approximately 6 weeks for Part A and approximately 10 weeks for Part B respectively.

Conditions

• Healthy
• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
DRUG	LY3938577	Administered SC.
DRUG	Placebo	Administered SC.
DRUG	Insulin degludec	Administered SC.

Timeline

• Start date: 2023-11-17
• Primary completion: 2024-06-28
• Completion: 2024-06-28
• First posted: 2023-11-15
• Last updated: 2024-07-24

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study